Business
Merck’s COVID-19 pill cuts risk of death, hospitalisation by half in study – Sydney Morning Herald
Merck and partner Ridgeback Biotherapeutics plan to seek US emergency use authorisation for the pill as soon as possible.
Merck & Co Incs experimental oral drug for COVID-19, molnupiravir, reduced by around 50 per cent the chance of hospitalisation or death for patients at risk of severe disease, according to interim clinical trial results announced on Friday.
Merck and partner…
Continue Reading
-
Noosa News16 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General14 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
Noosa News15 hours agoLyka Doggie Date Night at Moonlight Cinema
-
Business17 hours agoSolid superannuation gains continue to roll in